Longtime Bay Area biotech executive Dr. John Curd, who helped shepherd the Genentech cancer drugs Herceptin and Rituxan through clinical trials and most recently was president and chief medical officer of Threshold Pharmaceuticals Inc., died unexpectedly Wednesday at his home.
Curd, who joined Threshold (NASDAQ: THLD) in October 2007 and oversaw the Redwood City-based company’s clinical development work, apparently died of natural causes, the company said. He was 65.
No comments:
Post a Comment